Surrozen Presents Data Demonstrating The Promise Of Antibody-Based Wnt Mimetics In Treating Cornea Endothelial Dystrophies And Dry Eye Disease At The ARVO Annual Meeting
Surrozen Presents Data Demonstrating The Promise Of Antibody-Based Wnt Mimetics In Treating Cornea Endothelial Dystrophies And Dry Eye Disease At The ARVO Annual Meeting
-
In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the cornea
- Surrozen's antibody based Wnt mimetic also increased detectable tear volume production in dry eye disease models
-
在角膜內皮營養不良的臨床前模型中，基於Surrozen抗體的Wnt模擬物可減少角膜水腫並刺激角膜內皮細胞增殖
- Surrozen 基於抗體的 Wnt 模擬劑還增加了乾眼病模型中可檢測的淚液產量
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that preclinical data highlighting the potential for Surrozen's antibody-based Wnt mimetic technologies to treat cornea endothelial damage and Dry Eye Disease (DED) were presented on May 7, 2024 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle.
加利福尼亞州南舊金山，2024年5月9日（GLOBE NEWSWIRE）——Surrozen, Inc.（“Surrozen” 或 “公司”）（納斯達克股票代碼：SRZN）是一家開創選擇性激活組織修復和再生Wnt途徑的靶向療法的公司，今天宣佈，臨床前數據突顯了Surrozen基於抗體的Wnt模擬技術治療角膜內皮和損傷的潛力乾眼病（DED）於2024年5月7日在西雅圖舉行的視覺與眼科學研究協會（ARVO）年會上發表。
"We are pleased to present new data based on preclinical studies that demonstrate activation of the Wnt pathway leads to regeneration of cells in damaged eye tear gland tissue in Dry Eye Disease and proliferation of endothelial cells in Fuchs' Endothelial Cell Dystrophy, that can halt the loss of vision and blindness that develop as the diseases progress," said Yang Li, Ph.D. Executive Vice President of Research. "These early results are important as Fuchs' Endothelial Cell Dystrophy and Dry Eye Disease are severe diseases with few effective treatments available. We look forward to continuing our evaluation of this novel approach to tissue and cell regeneration utilizing our antibody based Wnt mimetic SWAP technologies."
研究執行副總裁楊麗博士說：“我們很高興提供基於臨床前研究的新數據，這些數據表明，Wnt通路的激活會導致乾眼病中受損眼淚腺組織中的細胞再生，並導致Fuchs內皮細胞營養不良中內皮細胞增殖，這可以阻止隨着疾病進展而出現的視力喪失和失明。”“這些早期結果很重要，因爲富克斯的內皮細胞營養不良症和乾眼病是嚴重的疾病，幾乎沒有有效的治療方法。我們期待利用我們基於抗體的Wnt模擬SWAP技術，繼續評估這種新的組織和細胞再生方法。”
Exploring Cornea Endothelium Regeneration with Selective Wnt Mimetics (Presentation, May 7, 2024, ARVO Annual Meeting)
使用選擇性 Wnt 模擬劑探索角膜內皮再生（演講，2024 年 5 月 7 日，ARVO 年會）
Preclinical studies evaluated whether Wnt signaling activation through Surrozen's antibody-based Wnt mimetic, that utilizes the SWAP (Surrozen Wnt signal activating proteins) technologies, can induce cornea endothelial cell proliferation and restore vision in cornea endothelial dystrophies when administered locally. The company evaluated a therapeutic approach to stimulate endothelial cell proliferation as human corneal endothelial cells have a limited capacity to regenerate.
臨床前研究評估了通過Surrozen基於抗體的Wnt模擬劑（利用SWAP（Surrozen Wnt信號激活蛋白）技術激活Wnt信號通路在局部給藥時是否可以誘發角膜內皮細胞增殖並恢復角膜內皮營養不良的視力。該公司評估了一種刺激內皮細胞增殖的治療方法，因爲人類角膜內皮細胞的再生能力有限。
The studies profiled both human normal and Fuchs' patient cornea endothelium which determined that Frizzled (Fzd)1/2/7 was expressed in these tissues and that activating Wnt signaling via Fzd1/2/7 in human endothelial cell cultures increases proliferation.
這些研究分析了人體正常人和富克斯患者角膜內皮，確定Frizzled（Fzd）1/2/7在這些組織中表達，通過人類內皮細胞培養物中的Fzd1/2/7激活Wnt信號傳導會增加增殖。
The lead molecule, a Surrozen Fzd 1/2/7 SWAP antibody, increased proliferation of endothelial cells in vitro in human cells. In a mouse model of cryoinjury, the Surrozen's antibody demonstrated:
- activation of Wnt signaling,
- reduced corneal edema and thickness, and
- demonstrated improved corneal clarity.
先導分子是 Surrozen Fzd 1/2/7 SWAP 抗體，可增加內皮細胞的增殖 體外 在人體細胞中。在小鼠冷凍損傷模型中，Surrozen的抗體表明：
-激活 Wnt 信號，
-減少角膜水腫和厚度，以及
-顯示角膜清晰度有所改善。
In eye diseases such as Fuchs' Endothelial Cell Dystrophy (FECD), there is a loss of endothelial cells which leads to corneal swelling, haziness and vision loss. There are about 2.9 million diagnosed patients with FECD. Current therapies are limited to endothelial transplant or resection once the disease is in a late stage. There is a significant area of unmet need for therapies that could mitigate disease progression and/or improve surgical efficacy. Results presented by Surrozen demonstrate that activation of the Wnt pathway has the potential to stimulate endothelial cell proliferation, reduce central corneal thickness and improve visual clarity.
在諸如Fuchs內皮細胞營養不良症（FECD）之類的眼部疾病中，內皮細胞會流失，從而導致角膜腫脹、模糊和視力喪失。大約有290萬確診的FECD患者。目前的療法僅限於疾病進入晚期後的內皮移植或切除術。對可以減緩疾病進展和/或提高手術療效的療法的需求有很大一部分未得到滿足。Surrozen提供的結果表明，Wnt通路的激活有可能刺激內皮細胞增殖，減少中央角膜厚度並提高視覺清晰度。
譯文內容由第三人軟體翻譯。